common.study.topics.clinical

Research of Nicotine Addiction

common.study.values.description

Translational Neuropsychopharmacology Research of Nicotine Addiction

This study will examine the effects of combining Varenicline (VRN) and N-acetylcysteine (NAC) on neural circuitry function and treating nicotine addiction. Healthy adult nicotine dependent cigarette smokers interested in quitting (n=110) will be randomized to one of four PBO-controlled conditions for 4 weeks: 1) VRN+NAC, 2) VRN+PBO, 3) NAC+PBO or 4) PBO+PBO. Following 1 week of medication, participants will be contingently reinforced for 3 days of smoking abstinence and be scanned using functional magnetic resonance imaging (fMRI) techniques, while nicotine deprived during a resting state and a cue-reactivity (CR) task. Participants will be followed over the next 3 weeks of treatment and clinical variables will be assessed.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - Varenicline (VRN)

VRN will be provided at the standard recommended dose (0.5 mg daily for 3 days, then 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for the remaining 21 days of active treatment.

Drug - N-Acetylcysteine (NAC)

NAC will be dosed at 1200 mg twice daily throughout the 28-day active treatment

Drug - Placebo

Matched placebo

participant.views.study.view.additional

participant.views.study.view.scientific-title

Translational Neuropsychopharmacology Research of Nicotine Addiction

common.study.values.clinical-trial-id

NCT02723162

participant.views.study.view.id

QeZXgb